Research programme: anti-P-selectin monoclonal antibodies - Novartis
Latest Information Update: 21 Nov 2016
Price :
$50 *
At a glance
- Originator Selexys Pharmaceuticals
- Developer Novartis
- Class Monoclonal antibodies
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Sickle cell anaemia
Most Recent Events
- 21 Nov 2016 Selexys Pharmaceuticals has been acquired and merged into Novartis
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA